 BioCryst Pharmaceuticals Inc NASDAQ: BCRX has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo berotralstat, showing a sustained reduction in hereditary angioedema HAE attacks patients. The HAE patients who were randomized to receive 150 mg of oral, once-daily Orladeyo at the start of the trial had an 80 average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. 